Becton, Dickinson and Company is a global medical technology company. The Company is engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, and others.
Company profile
Ticker
BDX
Exchange
Website
CEO
Thomas Polen
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Accuri Cytometers, Inc. • Adaptec Medical Devices LLC • Alverix, Inc. • Bard Access Systems, Inc. • Bard Acquisition Sub, Inc. • Bard ASDI, Inc. • Bard Brachytherapy, Inc. • Bard Devices, Inc. • Bard Global Holdings I LLC • Bard Global Holdings II LLC ...
IRS number
220760120
BDX stock data
Analyst ratings and price targets
Latest filings (excl ownership)
8-K
Amendments to Articles of Incorporation or Bylaws
21 Sep 23
25-NSE
Exchange delisting
14 Aug 23
10-Q
2023 Q3
Quarterly report
3 Aug 23
8-K
BD Reports Third Quarter Fiscal 2023 Financial Results
3 Aug 23
8-K
Departure of Directors or Certain Officers
24 Jul 23
UPLOAD
Letter from SEC
6 Jun 23
25-NSE
Exchange delisting
5 Jun 23
25-NSE
Exchange delisting
1 Jun 23
8-K
Regulation FD Disclosure
31 May 23
SD
Conflict minerals disclosure
25 May 23
Transcripts
BDX
Earnings call transcript
2023 Q3
3 Aug 23
BDX
Earnings call transcript
2023 Q2
4 May 23
BDX
Earnings call transcript
2023 Q1
2 Feb 23
BDX
Earnings call transcript
2022 Q4
10 Nov 22
BDX
Earnings call transcript
2022 Q3
4 Aug 22
BDX
Earnings call transcript
2022 Q2
5 May 22
BDX
Earnings call transcript
2022 Q1
3 Feb 22
BDX
Earnings call transcript
2021 Q4
4 Nov 21
BDX
Earnings call transcript
2021 Q3
5 Aug 21
BDX
Earnings call transcript
2021 Q2
6 May 21
Latest ownership filings
144
Notice of proposed sale of securities
15 Sep 23
4
Christopher DelOrefice
8 Sep 23
4
Richard Byrd
6 Sep 23
144
Notice of proposed sale of securities
5 Sep 23
4
Richard Byrd
5 Sep 23
4
Christopher DelOrefice
5 Sep 23
4
Claire Fraser
30 Aug 23
144
Notice of proposed sale of securities
29 Aug 23
4
David Hickey
14 Aug 23
144
Notice of proposed sale of securities
11 Aug 23
Financial summary
| Quarter (USD) | Jun 23 | Mar 23 | Dec 22 | Sep 22 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Sep 22 | Sep 21 | Sep 20 | Sep 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 1.02 bn | 1.02 bn | 1.02 bn | 1.02 bn | 1.02 bn | 1.02 bn |
| Cash burn (monthly) | 348.00 mm | 144.58 mm | (no burn) | (no burn) | (no burn) | (no burn) |
| Cash used (since last report) | 1.09 bn | 452.96 mm | n/a | n/a | n/a | n/a |
| Cash remaining | -66.25 mm | 571.04 mm | n/a | n/a | n/a | n/a |
| Runway (months of cash) | -0.2 | 3.9 | n/a | n/a | n/a | n/a |
Institutional ownership, Q2 2023
86.1% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 1494 |
| Opened positions | 143 |
| Closed positions | 125 |
| Increased positions | 548 |
| Reduced positions | 530 |
| 13F shares | Current |
|---|---|
| Total value | 65.67 tn |
| Total shares | 249.80 mm |
| Total puts | 779.96 k |
| Total calls | 1.18 mm |
| Total put/call ratio | 0.7 |
| Largest owners | Shares | Value |
|---|---|---|
| Vanguard | 25.41 mm | $6.71 tn |
| BLK Blackrock | 22.68 mm | $5.99 tn |
| T. Rowe Price | 14.24 mm | $3.75 tn |
| STT State Street | 12.76 mm | $3.37 tn |
| MS Morgan Stanley | 9.77 mm | $2.58 tn |
| Wellington Management | 9.66 mm | $2.55 tn |
| T. Rowe Price Investment Management | 6.24 mm | $1.64 tn |
| Geode Capital Management | 5.13 mm | $1.35 tn |
| BAC Bank Of America | 4.94 mm | $1.30 tn |
| Massachusetts Financial Services | 4.68 mm | $1.24 tn |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 7 Sep 23 | Christopher DelOrefice | Common Stock | Payment of exercise | Dispose F | No | No | 0 | 601 | 0.00 | 10,999 |
| 5 Sep 23 | Richard Byrd | Common Stock | Sell | Dispose S | No | No | 274.48 | 459 | 125.99 k | 3,444 |
| 1 Sep 23 | Christopher DelOrefice | Common Stock | Payment of exercise | Dispose F | No | No | 0 | 353 | 0.00 | 11,600 |
| 1 Sep 23 | Richard Byrd | Common Stock | Payment of exercise | Dispose F | No | No | 0 | 216 | 0.00 | 3,903 |
| 28 Aug 23 | Fraser Claire | Common Stock | Sell | Dispose S | No | No | 281.66 | 848 | 238.85 k | 21,608 |
News
How Is The Market Feeling About Becton Dickinson?
29 Sep 23
P/E Ratio Insights for Becton Dickinson
27 Sep 23
Jim Cramer Calls This Stock 'An Unbelievable Infrastructure Play': It's Up 43% In Past Year
21 Sep 23
Biden Administration Restarts Distribution Of Free At Home COVID-19 Tests, After Suspending For Year
21 Sep 23
Here's How Much You Would Have Made Owning Becton Dickinson Stock In The Last 20 Years
12 Sep 23
Press releases
Microbial Culture Market Value, Share, Competitive Analysis 2035
3 Oct 23
Global Medical Device Packaging Market Size Expected to Reach $50 Billion By 2028
26 Sep 23
BD Ranks in Top 10 for Transparency, Awarded Best Code of Conduct in 2023 U.S. Transparency Awards
19 Sep 23
Nation's Top 10 Most Transparent Companies Unveiled in Labrador's 2023 U.S. Transparency Awards
19 Sep 23
Navigate BioPharma Services, Inc. Announces Collaboration with BD (Becton, Dickinson and Company) to Advance Capabilities for Clinical Phases of Drug Development
7 Sep 23